Immunome (IMNM) Return on Capital Employed (2020 - 2026)
Immunome's (IMNM) quarterly Return on Capital Employed came in at 38.27% in Q1 2026, up 4542.0% YoY from 0.82% in Q1 2025, and up 23.8% on a QoQ basis from 50.22% in Q4 2025.
Immunome (IMNM) Return on Capital Employed (2020 - 2026) Analysis & Trends
Immunome (IMNM) has 7 years of Return on Capital Employed data on file, last reported at 38.27% in Q1 2026.
- Quarterly Return on Capital Employed rose 4542.0% year-over-year to 38.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.27% (up 4542.0% YoY) and the FY2025 annual result came in at 53.78%, up 16452.0% from the prior year.
- Return on Capital Employed grew to 38.27% in Q1 2026, from 50.22% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 38.27% in Q1 2026 to a low of 264.18% in Q1 2023.
- A 5-year average of 112.7% and a median of 104.0% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 18774 bps — and 2024, when it soared 14748 bps.
- Tracing IMNM's Return on Capital Employed over 5 years: stood at 184.83% in 2022, then jumped by 40 bps to 110.61% in 2023, then tumbled by 42 bps to 157.42% in 2024, then soared by 68 bps to 50.22% in 2025, then grew by 24 bps to 38.27% in 2026.
- The last three Return on Capital Employed figures came in at 38.27% (Q1 2026), 50.22% (Q4 2025), and 87.92% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | -48.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.57% |
| Mar 31, 2026 | -38.27% |
| Dec 31, 2025 | -50.22% |
| Sep 30, 2025 | -87.92% |
| Jun 30, 2025 | -75.72% |
| Mar 31, 2025 | -83.68% |
| Dec 31, 2024 | -157.42% |
| Sep 30, 2024 | -133.94% |
| Jun 30, 2024 | -101.31% |
| Mar 31, 2024 | -116.71% |
| Dec 31, 2023 | -110.61% |
| Sep 30, 2023 | -51.29% |
| Jun 30, 2023 | -144.51% |
| Mar 31, 2023 | -264.18% |
| Dec 31, 2022 | -184.83% |
| Sep 30, 2022 | -134.82% |
| Jun 30, 2022 | -104.00% |
| Mar 31, 2022 | -76.44% |
| Dec 31, 2021 | -49.90% |
| Sep 30, 2021 | -38.56% |